company background image
A314130 logo

Genome KOSDAQ:A314130 Stock Report

Last Price

₩2.88k

Market Cap

₩88.7b

7D

2.9%

1Y

-53.7%

Updated

27 Nov, 2024

Data

Company Financials

Genome & Company

KOSDAQ:A314130 Stock Report

Market Cap: ₩88.7b

A314130 Stock Overview

A clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. More details

A314130 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings have grown 4.8% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months compared to the KR market

Shareholders have been diluted in the past year

Does not have a meaningful market cap (₩89B)


Genome & Company Competitors

QuantaMatrix

KOSDAQ:A317690

₩120.4b

Dx & Vx

KOSDAQ:A180400

₩93.7b

KoBioLabs

KOSDAQ:A348150

₩112.2b

TiumBio

KOSDAQ:A321550

₩121.1b

Price History & Performance

Summary of all time highs, changes and price drops for Genome
Historical stock prices
Current Share Price₩2,880.00
52 Week High₩7,335.00
52 Week Low₩2,705.00
Beta1.0
11 Month Change-24.11%
3 Month Change-27.00%
1 Year Change-53.66%
33 Year Change-82.28%
5 Year Change-85.23%
Change since IPO-38.26%

Recent News & Updates

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Nov 13
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Sep 06
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Is Genome (KOSDAQ:314130) A Risky Investment?

Jul 03
Is Genome (KOSDAQ:314130) A Risky Investment?

Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

May 27
Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Apr 11
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

Mar 08
Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

Recent updates

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Nov 13
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Sep 06
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump

Is Genome (KOSDAQ:314130) A Risky Investment?

Jul 03
Is Genome (KOSDAQ:314130) A Risky Investment?

Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

May 27
Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump

Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Apr 11
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump

Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

Mar 08
Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?

Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans

Mar 17
Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

A314130KR BiotechsKR Market
7D2.9%-4.2%1.9%
1Y-53.7%19.5%-2.6%

Return vs Industry: A314130 underperformed the KR Biotechs industry which returned 19.5% over the past year.

Return vs Market: A314130 underperformed the KR Market which returned -2.6% over the past year.

Price Volatility

Is A314130's price volatile compared to industry and market?
A314130 volatility
A314130 Average Weekly Movement11.6%
Biotechs Industry Average Movement8.0%
Market Average Movement5.7%
10% most volatile stocks in KR Market11.6%
10% least volatile stocks in KR Market2.7%

Stable Share Price: A314130's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A314130's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
201590Jisoo Paegenomecom.co.kr

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements.

Genome & Company Fundamentals Summary

How do Genome's earnings and revenue compare to its market cap?
A314130 fundamental statistics
Market cap₩88.73b
Earnings (TTM)-₩37.88b
Revenue (TTM)₩23.92b

3.7x

P/S Ratio

-2.4x

P/E Ratio

Is A314130 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A314130 income statement (TTM)
Revenue₩23.92b
Cost of Revenue₩11.72b
Gross Profit₩12.20b
Other Expenses₩50.09b
Earnings-₩37.88b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.22k
Gross Margin51.00%
Net Profit Margin-158.35%
Debt/Equity Ratio20.6%

How did A314130 perform over the long term?

See historical performance and comparison